Medincell announces the suspension of listing of its shares on Euronext Paris
08 Maggio 2024 - 9:00AM
Business Wire
Regulatory News:
The listing of the Medincell (Paris:MEDCL) shares on Euronext
Paris has been suspended at the request of the Company, pending the
publication of a press release. Trading on Euronext Paris will
resume tomorrow at the opening of markets.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical
licensing company developing long-acting injectable drugs in many
therapeutic areas. Our innovative treatments aim to guarantee
compliance with medical prescriptions, to improve the effectiveness
and accessibility of medicines, and to reduce their environmental
footprint. They combine active pharmaceutical ingredients with our
proprietary BEPO® technology which controls the delivery of a drug
at a therapeutic level for several days, weeks or months from the
subcutaneous or local injection of a simple deposit of a few
millimeters, entirely bioresorbable. The first treatment based on
BEPO® technology, intended for the treatment of schizophrenia, was
approved by the FDA in April 2023, and is now distributed in the
United States by Teva under the name UZEDY™ (BEPO® technology is
licensed to Teva under the name SteadyTeq™). We collaborate with
leading pharmaceutical companies and foundations to improve global
health through new treatment options. Based in Montpellier,
Medincell currently employs more than 140 people representing more
than 25 different nationalities.
UZEDY™ and SteadyTeq™ are trademarks of Teva Pharmaceuticals
www.medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240508143991/en/
David Heuzé Head of Corporate and Financial
Communications, and ESG david.heuze@medincell.com / +33 (0)6 83 25
21 86 Grace Kim Head of US Financial Strategy & IR
grace.kim@medincell.com / +1 (646) 991-4023 Nicolas Mérigeau
Media Relations medincell@newcap.eu / +33 (0)1 44 71 94 94
Louis-Victor Delouvrier/Alban Dufumier Investor Relations
France medincell@newcap.eu / +33 (0)1 44 71 94 94
Grafico Azioni Medincell (EU:MEDCL)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Medincell (EU:MEDCL)
Storico
Da Gen 2024 a Gen 2025
